Unknown

Dataset Information

0

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.


ABSTRACT: Purpose: We evaluated biodistribution and tumor targeting of 89Zr-lumretuzumab before and during treatment with lumretuzumab, a human epidermal growth factor receptor 3 (HER3)-targeting monoclonal antibody.Experimental Design: Twenty patients with histologically confirmed HER3-expressing tumors received 89Zr-lumretuzumab and underwent positron emission tomography (PET). In part A, 89Zr-lumretuzumab was given with additional, escalating doses of unlabeled lumretuzumab, and scans were performed 2, 4, and 7 days after injection to determine optimal imaging conditions. In part B, patients were scanned following tracer injection before (baseline) and after a pharmacodynamic (PD)-active lumretuzumab dose for saturation analysis. HER3 expression was determined immunohistochemically in skin biopsies. Tracer uptake was calculated as standardized uptake value (SUV).Results: Optimal PET conditions were found to be 4 and 7 days after administration of 89Zr-lumretuzumab with 100-mg unlabeled lumretuzumab. At baseline using 100-mg unlabeled lumretuzumab, the tumor SUVmax was 3.4 (±1.9) at 4 days after injection. SUVmean values for normal blood, liver, lung, and brain tissues were 4.9, 6.4, 0.9 and 0.2, respectively. Saturation analysis (n = 7) showed that 4 days after lumretuzumab administration, tumor uptake decreased by 11.9% (±8.2), 10.0% (±16.5), and 24.6% (±20.9) at PD-active doses of 400, 800, and 1,600 mg, respectively, when compared with baseline. Membranous HER3 was completely downregulated in paired skin biopsies already at and above 400-mg lumretuzumab.Conclusions: PET imaging showed biodistribution and tumor-specific 89Zr-lumretuzumab uptake. Although, PD-active lumretuzumab doses decreased 89Zr-lumretuzumab uptake, there was no clear evidence of tumor saturation by PET imaging as the tumor SUV did not plateau with increasing doses. Clin Cancer Res; 23(20); 6128-37. ©2017 AACR.

SUBMITTER: Bensch F 

PROVIDER: S-EPMC5642894 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications


<b>Purpose:</b> We evaluated biodistribution and tumor targeting of <sup>89</sup>Zr-lumretuzumab before and during treatment with lumretuzumab, a human epidermal growth factor receptor 3 (HER3)-targeting monoclonal antibody.<b>Experimental Design:</b> Twenty patients with histologically confirmed HER3-expressing tumors received <sup>89</sup>Zr-lumretuzumab and underwent positron emission tomography (PET). In part A, <sup>89</sup>Zr-lumretuzumab was given with additional, escalating doses of unla  ...[more]

Similar Datasets

| S-EPMC6604691 | biostudies-literature
| S-EPMC5680796 | biostudies-literature
| S-EPMC8508546 | biostudies-literature
| S-EPMC5998059 | biostudies-literature
| S-EPMC8488777 | biostudies-literature
| 2750119 | ecrin-mdr-crc
| S-EPMC4745807 | biostudies-other
| S-EPMC5486818 | biostudies-literature
| S-EPMC4116087 | biostudies-literature
| S-EPMC6203283 | biostudies-literature